Valencene

About Evolva Holding SA

Evolva was a publicly traded company that leveraged synthetic biology and precision fermentation to produce high-value compounds for the health, nutrition, and wellness markets. Its key commercial and development-stage products included resveratrol, nootkatone, and vanillin. Following severe financial distress in 2023, the company sold its main business units, underwent liquidation proceedings, and was delisted, marking the end of its operations as an independent entity.

Therapeutic Areas